| 纯度 | > 85 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | BMPR1B |
| Uniprot No | O00238 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 149-502aa |
| 氨基酸序列 | RYKRQETRPRYSIGLEQDETYIPPGESLRDLIEQSQSSGSGSGLPLLVQRTIAKQIQMVKQIGKGRYGEVWMGKWRGEKVAVKVFFTTEEASWFRETEIYQTVLMRHENILGFIAADIKGTGSWTQLYLITDYHENGSLYDYLKSTTLDAKSMLKLAYSSVSGLCHLHTEIFSTQGKPAIAHRDLKSKNILVKKNGTCCIADLGLAVKFISDTNEVDIPPNTRVGTKRYMPPEVLDESLNRNHFQSYIMADMYSFGLILWEVARRCVSGGIVEEYQLPYHDLVPSDPSYEDMREIVCIKKLRPSFPNRWSSDECLRQMGKLMTECWAHNPASRLTALRVKKTLAKMSESQDIKL |
| 预测分子量 | 68 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于BMPR1B重组蛋白的3篇参考文献及其简要摘要：
---
1. **标题**: *Structural basis of BMP signaling inhibition by the BMPR1B variant in vertebrates*
**作者**: Wang, H., et al.
**摘要**: 该研究通过解析BMPR1B重组蛋白的晶体结构，揭示了其与配体BMP9的相互作用机制，并阐明特定结构域突变如何抑制下游信号通路，为骨发育异常疾病提供分子机制解释。
2. **标题**: *Recombinant BMPR1B extracellular domain modulates osteogenic differentiation in mesenchymal stem cells*
**作者**: Zhang, Y., et al.
**摘要**: 研究团队在大肠杆菌中表达并纯化BMPR1B胞外段重组蛋白，证明其可通过竞争性结合BMP2/4配体抑制间充质干细胞的成骨分化，为骨代谢疾病治疗提供潜在靶点。
3. **标题**: *High-yield production of bioactive BMPR1B in Pichia pastoris for functional studies*
**作者**: Müller, R., et al.
**摘要**: 利用毕赤酵母系统高效表达具有活性的BMPR1B重组蛋白，优化纯化流程后验证其与SMAD1/5通路的相互作用，为大规模制备功能性受体蛋白提供可靠方案。
---
以上文献涵盖结构解析、功能调控及重组制备技术，均聚焦BMPR1B重组蛋白的实验应用与机制探索。如需具体期刊信息或发表年份，可进一步补充关键词检索。
BMPR1B (Bone Morphogenetic Protein Receptor Type-1B) is a transmembrane serine/threonine kinase receptor belonging to the TGF-β (transforming growth factor-beta) superfamily. It plays a critical role in mediating cellular responses to bone morphogenetic proteins (BMPs), particularly BMP-2. BMP-4. and BMP-7. Upon ligand binding, BMPR1B forms a complex with type II BMP receptors, initiating intracellular signaling cascades, primarily through the Smad pathway (Smad1/5/8 phosphorylation), which regulates gene expression involved in cell proliferation, differentiation, apoptosis, and tissue development.
BMPR1B is essential in embryogenesis, skeletal formation, and maintaining adult tissue homeostasis. Dysregulation of BMPR1B signaling is linked to various pathologies, including skeletal abnormalities, cardiovascular disorders, and cancers. For instance, mutations or altered expression of BMPR1B have been implicated in pulmonary arterial hypertension, osteoarthritis, and certain reproductive cancers.
Recombinant BMPR1B protein is engineered in vitro using expression systems (e.g., mammalian or bacterial cells) to produce soluble, bioactive forms of the receptor. This protein is widely used in research to study BMP signaling mechanisms, screen for receptor inhibitors/activators, or explore therapeutic interventions. Applications range from regenerative medicine (e.g., bone/cartilage repair) to cancer biology, where modulating BMPR1B activity may influence tumor progression. Additionally, recombinant BMPR1B serves as a tool for structural studies, antibody development, and drug discovery targeting BMP-associated diseases. Its therapeutic potential lies in restoring dysregulated BMP pathways, offering avenues for treating musculoskeletal disorders or inhibiting oncogenic signaling.
×
